肝细胞癌与TERT,TP53和CTNNB1的同时突变:人工智能有没有作用?
Stefano Chillotti1, Thais Maloberti2, Alessio Degiovanni3
1Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; School of Anatomic Pathology, Department of Biomedical and Neuromotor Sciences, University of Bologna.
Critical reviews in oncogenesis
|November 16, 2023
概括
这项研究详细介绍了两个罕见的肝细胞癌 (HCC) 病例,同时具有TP53,CTNNB1和TERT促销基因突变. 所有突变都存在于所有瘤区域,表明单个克隆具有多种表型.
科学领域:
- 肝胆病原体的发生
- 癌症基因组学 癌症基因组学
- 分子瘤学分子瘤学
背景情况:
- 肝细胞癌 (HCC) 呈现出显著的形态和遗传异质性.
- 在HCC中常见的驱动突变包括TP53,CTNNB1和TERT促进器突变.
- 对病理学家来说,区分HCC亚型是非常具有挑战性的.
研究的目的:
- 报告和分析两个罕见的HCC病例,同时发生TP53,CTNNB1和TERT促剂的共变.
- 研究在形态上不同的HCC区域内的克隆结构和突变分布.
- 探索人工智能在HCC分类中的潜力.
主要方法:
- 对两名同时出现TP53,CTNNB1和TERT促进器突变的HCK患者的案例研究.
- 针对β-catenin和谷氨胺合成酶表达的自动免疫组织化学.
- 下一代测序 (NGS) 分析微切割的瘤区域,具有不同等级和蛋白质表达.
主要成果:
- 这两种病例均呈现了TP53,CTNNB1和TERT-促进体的同时突变.
- NGS分析显示,在所有分析的微区域中,所有三种突变的共同存在,不论瘤等级或蛋白质表达.
- 在不同瘤区域之间没有发现突变负担的显著差异.
结论:
- 这些发现表明,这些HCCs源于一个单一的瘤克隆,其中包含所有驱动突变,从而导致表型多样性.
- 观察到的瘤等级和蛋白质表达的异质性很可能是由单个克隆驱动的,而不是由不同的亚克隆驱动的.
- 突变预测人工智能模型显示出改善形态遗传HCC分类的灵敏度,特异性和可重复性的承诺.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.9K
08:40A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
Published on: August 7, 2020
6.3K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
